Marco Mielcarek

University of Washington — United States

Medicine · Health Sciences

45h-index9.1kcitations192works2.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Hematopoietic Stem Cell Transplantation(138), Acute Myeloid Leukemia Research(42), Immune Cell Function and Interaction(33), Renal Transplantation Outcomes and Treatments(26), Acute Lymphoblastic Leukemia research(26)

Publications192 total

The Risk of BK-Virus Hemorrhagic Cystitis in the Era of Post-Transplantation Cyclophosphamide
Transplantation and Cellular Therapy·2026
New Insights Into Factors Shaping <scp>CMV</scp> ‐Specific T‐Cell Polyfunctionality After Hematopoietic Cell Transplantation
American Journal of Hematology·2025Open Access
Matched unrelated vs haploidentical donor hematopoietic cell transplantation using posttransplant cyclophosphamide
Blood Advances·2025· 2 citedOpen Access
Sirolimus and Cyclosporine With Post-Transplant Cyclophosphamide or Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis in Unrelated Donor Hematopoietic Cell Transplantation
Journal of Clinical Oncology·2025· 1 cited
Hematopoietic Cell Transplantation, Version 3.2025, NCCN Clinical Practice Guidelines In Oncology
Journal of the National Comprehensive Cancer Network·2025· 4 cited
A Randomized Phase II Study Comparing Cyclosporine and Sirolimus Combined with MMF or Post-Transplant Cyclophosphamide As Gvhd Prophylaxis after HLA-Matched or -Mismatched Unrelated Mobilized Blood Cell Transplantation Using Nonmyeloablative or Reduced-Intensity Conditioning
Transplantation and Cellular Therapy·2025
Characterization of Chronic Graft-Versus-Host Disease Onset, Severity, and Treatment after Post-Transplantation Cyclophosphamide-Based Gvhd Prophylaxis
Transplantation and Cellular Therapy·2025
Twenty-Six-Year Follow-up of Donor-Derived Del(20q) after Allogeneic Hematopoietic Cell Transplantation
Transplantation and Cellular Therapy·2025Open Access
P-2001. Limited Yield of Weekly SARS-CoV-2 Surveillance Testing Among Asymptomatic Hematopoietic Cell Transplant and Chimeric Antigen Receptor T-Cell Therapy Recipients
Open Forum Infectious Diseases·2025Open Access
Limited yield of SARS-CoV-2 screening in asymptomatic hematopoietic cell transplant and chimeric antigen receptor T-cell therapy patients
Antimicrobial Stewardship & Healthcare Epidemiology·2025Open Access
CMV Specific T Cell Polyfunctionality after HCT: A Detailed Analysis of the Impact of Steroid Exposure, Immunosuppressive Regimens and Viral Reactivation
Blood·2024
COVID-19 Outcomes Among Hematopoietic Cell Transplant and Chimeric Antigen Receptor T-Cell Recipients in the Era of SARS-CoV-2 Omicron Variants and COVID-19 Therapeutics
Transplantation and Cellular Therapy·2024· 5 citedOpen Access
Optimizing Autologous Stem Cell Transplantation in Multiple Myeloma: The Impact of Intensive Chemomobilization
Transplantation and Cellular Therapy·2024· 1 citedOpen Access
The Effect of Gastrointestinal Graft-Versus-Host Disease and Diarrhea on the Pharmacokinetic Profile of Sotrovimab in Hematopoietic Stem Cell Transplant Recipients
The Journal of Infectious Diseases·2024· 5 citedOpen Access
Outcomes in Hematopoietic Cell Transplant and Chimeric Antigen Receptor T-Cell Therapy Recipients With Pre–Cellular Therapy SARS-CoV-2 Infection
Clinical Infectious Diseases·2024· 13 citedOpen Access
Risk Factors for Pre-CAR-T Attrition Among Large B-Cell Lymphoma (LBCL) Patients
Transplantation and Cellular Therapy·2024
Differential Association between Blood Glucose Levels and Nonrelapse Mortality after Allogeneic Hematopoietic Cell Transplantation Based on Presence or Absence of Preexisting Diabetes
Transplantation and Cellular Therapy·2024· 3 citedOpen Access
Cryopreservation of Growth Factor-Mobilized Peripheral Blood Stem Cells Does Not Compromise Major Outcomes after Allogeneic Hematopoietic Cell Transplantation: A Single-Center Experience
Transplantation and Cellular Therapy·2023· 7 cited
Impact of Donor Statin Treatment on Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation
Transplantation and Cellular Therapy·2023· 3 citedOpen Access
Revisiting the Utility of Granulocyte Colony-Stimulating Factor Post-Autologous Hematopoietic Stem Cell Transplantation for Outpatient-Based Transplantations
Transplantation and Cellular Therapy·2023· 3 citedOpen Access
page 1 of 10Next →

Frequent Co-authors

Rainer Storb(26), Barry E. Storer(19), Paul J. Martin(18), Brenda M. Sandmaier(17), Mary E.D. Flowers(15), Frederick R. Appelbaum(12), David G. Maloney(11), H. Joachim Deeg(9), Thomas R. Chauncey(8), Paul A. Carpenter(7), Michael B. Maris(7), Richard A. Nash(6), Mohamed L. Sorror(6), Michael A. Pulsipher(6), Terry Furlong(6), Yoshihiro Inamoto(5), Wendy M. Leisenring(5), Michael Boeckh(5), Beverly Torok‐Storb(5), Ann E. Woolfrey(4)